FMP
Galecto, Inc.
GLTO
NASDAQ
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
0.702 USD
0.0278 (3.96%)
About
ceo
Dr. Hans T. Schambye M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://galecto.com
exchange
NASDAQ
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in ...
CIK
0001800315
ISIN
US36322Q1076
CUSIP
36322Q107
Address
75 State Street
Phone
457 070 5210
Country
US
Employee
13
IPO Date
Oct 29, 2020
Summary
CIK
0001800315
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
36322Q107
ISIN
US36322Q1076
Country
US
Price
0.7
Beta
1.25
Volume Avg.
227.78k
Market Cap
19.04M
Shares
-
52-Week
0.5-3.7
DCF
0.8
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.49
P/B
-
Website
https://galecto.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GLTO News
It looks like there's no news available.
